Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Cohort Study

Background: The SARS-CoV-2 pandemic has resulted in enormous morbidity and mortality worldwide, yet no medications to date are proven to improve clinical outcomes in hospitalized COVID-19 patients. Famotidine is commonly used for gastric acid suppression but also has recently gained attention as an antiviral that may inhibit SARS-CoV-2 replication. Objective: To determine whether famotidine use is associated with improved clinical outcomes in patients with COVID-19 initially hospitalized to a non-intensive care setting. Design: Retrospective cohort study. Setting: Inpatients at a single academic medical center. Participants: Consecutive hospitalized patients with COVID-19 infection from February 25 to April 13, 2020. Measurements: Famotidine use (exposure); intubation or death (primary outcome) Results: 1,620 hospitalized patients with COVID-19 were analyzed including 84 (5.1%) who received famotidine within 24 hours of hospital admission. There were no differences between famotidine users and non-users in age, body mass index, or comorbidities including diabetes or hypertension. 340 (21%) patients met the study composite outcome of death or intubation. Use of famotidine was associated with reduced risk for death or intubation (adjusted hazard ratio (aHR) 0.40, 95% CI 0.20-0.81) and also with reduced risk for death alone (aHR 0.29, 95% CI 0.11-0.78). Proton pump inhibitors, which also suppress gastric acid, were not associated with reduced risk for death or intubation. In patients without COVID-19 hospitalized during the same time period, no association was observed between use of famotidine and death or intubation. Limitations: Retrospective analysis; non-randomized exposure. Conclusion: Famotidine use is associated with reduced risk of intubation or death in hospitalized COVID-19 patients. Randomized controlled trials are warranted to determine whether famotidine therapy improves outcomes in hospitalized COVID-19 patients.

[1]  Carl H. June,et al.  Cytokine release syndrome in severe COVID-19 , 2020, Science.

[2]  Nathaniel Hupert,et al.  Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.

[3]  Lianyong Liu,et al.  Existing bitter medicines for fighting 2019‐nCoV‐associated infectious diseases , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  S. Merler,et al.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.

[5]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[6]  Lixia Chen,et al.  Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods , 2020, Acta Pharmaceutica Sinica B.

[7]  W. Liang,et al.  Clinical characteristics of 2019 novel coronavirus infection in China , 2020, medRxiv.

[8]  W. Liu,et al.  Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV , 2020, Chembiochem : a European journal of chemical biology.

[9]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[10]  A. Califano,et al.  Bone Marrow Myeloid Cells Regulate Myeloid-Biased Hematopoietic Stem Cells via a Histamine-Dependent Feedback Loop. , 2017, Cell stem cell.

[11]  Rolf Hilgenfeld,et al.  Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs , 2003, Science.

[12]  A. Bourinbaiar,et al.  The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents. , 1996, Life sciences.

[13]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .